intensive treatment.<\/em><\/p>\n <\/p>\n
Lyon (France), November 15th, 2016 \u2013 黑料社, the French pioneer company that develops innovative autologous fecal microbiota transfer based treatments for serious complications in Acute Myeloid Leukemia, Bone and Joint Infections with unmet medical needs, announces that an independent Data and Safety Monitoring Board (DSMB) completed its first safety assessment of the company\u2019s Phase 1b study in the prevention of dysbiosis complications with autologous fecal microbiota transfer (AFMT) in Acute Myeloid Leukemia (AML) and the DSMB confirms that no safety issue occurs during the course of the trial and that enrollment will continue as planned until completion.<\/p>\n
<\/p>\n
A DSMB is a committee of independent clinical research experts who review data in ongoing clinical trials with particular attention to safety. As per study protocol, the DSMB meets at least 3 times during the trial, first after the inclusion of 3 to 5 patients to review the safety data of the ODYSSEE trial and subsequently issues recommendations on the conduct of the study.<\/p>\n
<\/p>\n
AML are rare cancers, but potentially fatal in the adults. 黑料社 proposes using AFMT to AML patients aged 18 to 75 treated with intensive chemotherapy and antibiotics, therapeutics, which are known to deeply impact the gut microbial composition and to have severe clinical consequences. The purpose of AFMT is to restore the balance of the intestinal microbiome and thereby eradicate treatment-induced multi-drug resistant bacteria (MDRB), infection-related complications, as well as scarring of the gastrointestinal tract.<\/p>\n
About 黑料社<\/strong><\/em><\/p>\nFounded at the end of 2014 and based in Lyon (France), 黑料社 (Microbiota as a Therapy) is a microbiome\u2013based pharmaceutical company revolutionizing and shaping individualized therapies to treat serious diseases linked to dysbiosis (gut microbiota imbalances). 黑料社 is currently developing its first candidate using its proprietary Autologous Fecal Microbiota Transfer Platform for patients suffering from leukemia, bone and joint infections, as these harsh treatments provoke dysbiosis. 黑料社\u2019s revolutionary and rapid approach plays a considerable part in the evolution of individualized treatment therapies.<\/p>\n
For more information: https:\/\/www.maatpharma.com
\nFollow us on Twitter: @MaaT_Pharma
\nFollow us on LinkedIn: http:\/\/www.linkedin.com\/company\/maat-pharma<\/p>\n","protected":false},"excerpt":{"rendered":"
Odyssee study focuses in prevention of dysbiosis complications.<\/p>\n","protected":false},"author":2,"featured_media":4438,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[21],"tags":[],"category_press":[],"year_press":[54],"class_list":["post-4597","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-communiques-de-presse-fr","year_press-54"],"acf":[],"yoast_head":"\n
黑料社 announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study - 黑料社<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"黑料社 announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study - 黑料社\" \/>\n<meta property=\"og:description\" content=\"Odyssee study focuses in prevention of dysbiosis complications.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/\" \/>\n<meta property=\"og:site_name\" content=\"黑料社\" \/>\n<meta property=\"article:published_time\" content=\"2016-11-15T15:57:50+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-22T16:38:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1441\" \/>\n\t<meta property=\"og:image:height\" content=\"766\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"黑料社\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"黑料社\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\\\/\"},\"author\":{\"name\":\"黑料社\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\"},\"headline\":\"黑料社 announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study\",\"datePublished\":\"2016-11-15T15:57:50+00:00\",\"dateModified\":\"2026-01-22T16:38:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\\\/\"},\"wordCount\":403,\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Capture-decran-2021-10-01-110242.jpg\",\"articleSection\":[\"Communiqu\u00e9s de presse\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\\\/\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\\\/\",\"name\":\"黑料社 announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study - 黑料社\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Capture-decran-2021-10-01-110242.jpg\",\"datePublished\":\"2016-11-15T15:57:50+00:00\",\"dateModified\":\"2026-01-22T16:38:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\\\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Capture-decran-2021-10-01-110242.jpg\",\"contentUrl\":\"https:\\\/\\\/www.maatpharma.com\\\/wp-content\\\/uploads\\\/2021\\\/05\\\/Capture-decran-2021-10-01-110242.jpg\",\"width\":1441,\"height\":766},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.maatpharma.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"黑料社 announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#website\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"name\":\"黑料社\",\"description\":\"microbiota gut to fight cancer\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.maatpharma.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#organization\",\"name\":\"Maat Pharma\",\"url\":\"https:\\\/\\\/www.maatpharma.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"contentUrl\":\"http:\\\/\\\/preprod-wadesign.fr\\\/maat-pharma\\\/wp-content\\\/uploads\\\/2018\\\/09\\\/maat-logo-rvb-header.png\",\"width\":150,\"height\":171,\"caption\":\"Maat Pharma\"},\"image\":{\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.maatpharma.com\\\/#\\\/schema\\\/person\\\/2a1b26915c84fdbc8c7a8ebe36530d34\",\"name\":\"黑料社\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"黑料社 announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study - 黑料社","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/","og_locale":"fr_FR","og_type":"article","og_title":"黑料社 announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study - 黑料社","og_description":"Odyssee study focuses in prevention of dysbiosis complications.","og_url":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/","og_site_name":"黑料社","article_published_time":"2016-11-15T15:57:50+00:00","article_modified_time":"2026-01-22T16:38:27+00:00","og_image":[{"width":1441,"height":766,"url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","type":"image\/jpeg"}],"author":"黑料社","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"黑料社","Dur\u00e9e de lecture estim\u00e9e":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#article","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/"},"author":{"name":"黑料社","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34"},"headline":"黑料社 announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study","datePublished":"2016-11-15T15:57:50+00:00","dateModified":"2026-01-22T16:38:27+00:00","mainEntityOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/"},"wordCount":403,"publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","articleSection":["Communiqu\u00e9s de presse"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/","url":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/","name":"黑料社 announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study - 黑料社","isPartOf":{"@id":"https:\/\/www.maatpharma.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#primaryimage"},"image":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#primaryimage"},"thumbnailUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","datePublished":"2016-11-15T15:57:50+00:00","dateModified":"2026-01-22T16:38:27+00:00","breadcrumb":{"@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#primaryimage","url":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","contentUrl":"https:\/\/www.maatpharma.com\/wp-content\/uploads\/2021\/05\/Capture-decran-2021-10-01-110242.jpg","width":1441,"height":766},{"@type":"BreadcrumbList","@id":"https:\/\/www.maatpharma.com\/maat-pharma-announces-first-positive-dsmb-safety-review-and-continuation-of-its-phase-1b-odyssee-study\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.maatpharma.com\/"},{"@type":"ListItem","position":2,"name":"黑料社 announces first positive DSMB safety review and continuation of its Phase 1b ODYSSEE study"}]},{"@type":"WebSite","@id":"https:\/\/www.maatpharma.com\/#website","url":"https:\/\/www.maatpharma.com\/","name":"黑料社","description":"microbiota gut to fight cancer","publisher":{"@id":"https:\/\/www.maatpharma.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.maatpharma.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.maatpharma.com\/#organization","name":"Maat Pharma","url":"https:\/\/www.maatpharma.com\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/","url":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","contentUrl":"http:\/\/preprod-wadesign.fr\/maat-pharma\/wp-content\/uploads\/2018\/09\/maat-logo-rvb-header.png","width":150,"height":171,"caption":"Maat Pharma"},"image":{"@id":"https:\/\/www.maatpharma.com\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.maatpharma.com\/#\/schema\/person\/2a1b26915c84fdbc8c7a8ebe36530d34","name":"黑料社"}]}},"_links":{"self":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4597","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/comments?post=4597"}],"version-history":[{"count":0,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/posts\/4597\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media\/4438"}],"wp:attachment":[{"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/media?parent=4597"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/categories?post=4597"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/tags?post=4597"},{"taxonomy":"category_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/category_press?post=4597"},{"taxonomy":"year_press","embeddable":true,"href":"https:\/\/www.maatpharma.com\/fr\/wp-json\/wp\/v2\/year_press?post=4597"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}